Articles

Long-Term Efficacy, Safety, and Tolerability of Alirocumab in 8242 Patients Eligible for 3 to 5 Years of Placebo-Controlled Observation in the ODYSSEY OUTCOMES Trial

Goodman SG, Steg PG, Poulouin Y, et al.

First published: September 13, 2023  DOI: 10.1161/JAHA.122.029216